Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 14/20 | 0.63 |
| ▸ | VEGFA | P15692 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19872151 | 0.84 | VEGFA (0.63) | EPAS1VEGFA | |
| SCHEMBL19872208 | 0.84 | VEGFA (0.63) | EPAS1VEGFA | |
| SCHEMBL19872164 | 0.83 | EPAS1 (0.65) | EPAS1VEGFA | |
| SCHEMBL18036719 | 0.78 | EPAS1 (0.67) | EPAS1VEGFA | |
| SCHEMBL16560960 | 0.78 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL19872168 | 0.77 | EPAS1 (0.65) | EPAS1VEGFA | |
| SCHEMBL19872363 | 0.74 | EPAS1 (0.53) | EPAS1VEGFA | |
| SCHEMBL19872163 | 0.71 | EPAS1 (0.49) | EPAS1VEGFACNR2CNR1 | |
| SCHEMBL16560802 | 0.69 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL18036835 | 0.69 | VEGFA (0.86) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | PELOTON THERAPEUTICS INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10807948-B2 | Aromatic compounds and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190048421-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190015377-A1 | Compositions for Use in Treating Pulmonary Arterial Hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | PELOTON THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 47/4885PTGS1 108/4885 |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | EPAS1 2505/4885VEGFA 189/4885PTGS1 1044/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | EPAS1 16/4885VEGFA 45/4885PTGS1 129/4885 |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 14/4885VEGFA 641/4885PTGS1 359/4885 |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | HIF1AN, EGLN2, EGLN3 | EPAS1 30/4885VEGFA 2429/4885PTGS1 14/4885 |
| US-20190048421-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 14/4885VEGFA 641/4885PTGS1 359/4885 |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | MYLK, TNNI3, PDE2A | EPAS1 450/4885VEGFA 34/4885PTGS1 112/4885 |
| US-20190015377-A1 | Compositions for Use in Treating Pulmonary Arterial Hypertension | MYLK, TNNI3, PDE2A | EPAS1 450/4885VEGFA 34/4885PTGS1 112/4885 |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 89/4885PTGS1 132/4885 |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | MYLK, TNNI3, PDE2A | EPAS1 450/4885VEGFA 34/4885PTGS1 112/4885 |
| US-10807948-B2 | Aromatic compounds and uses thereof | VHL, HIF1AN, HIF1A | EPAS1 17/4885VEGFA 910/4885PTGS1 252/4885 |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | HIF1A, HIF1AN, VHL | EPAS1 13/4885VEGFA 419/4885PTGS1 475/4885 |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 89/4885PTGS1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.